1. Metabolic Enzyme/Protease
  2. LXR


LXRs (Liver X Receptor α and β) are nuclear receptors that act as ligand-activated transcription factors. LXR activation causes upregulation of genes involved in reverse cholesterol transport (RCT), including ABCA1 and ABCG1 transporters, in macrophage and intestine.

LXRα/β are ligand-activated transcription factors of the nuclear hormone receptor superfamily that stimulate transcription of several genes, including ABCA1 and apoE. LXRα and LXRβ respond to the same oxysterol ligands and activate transcription as obligate heterodimeric complexes with retinoid X receptors.

Synthetic LXR agonists activate both LXRα and LXRβ, cross the blood-brain barrier, and efficiently induce expression of LXR target genes including ABCA1 and apoE.

LXR Related Products (16):

Cat. No. Product Name Effect Purity
  • HY-10627A
    GW3965 hydrochloride Agonist 99.70%
    GW3965 hydrochloride is a potent, selective LXR agonist for hLXRα and hLXRβ with EC50 of 190 and 30 nM, respectively.
  • HY-10626
    T0901317 Agonist 99.64%
    T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 (mu)M, respectively, inhibits nuclear factor/(kappa)B (NF/(kappa)B).
  • HY-10629
    LXR-623 Agonist 99.40%
    LXR-623 is a highly brain-penetrant LXRα-partial/LXRβ-full agonist, with IC50 of 179 and 24 nM for LXR-β and the LXR-α subtype, respectively.
  • HY-16972
    SR9243 Antagonist
    SR9243 is a liver-X-receptor (LXR) inverse agonist that induces LXR-corepressor interaction.
  • HY-18282
    AZ876 Agonist 99.76%
    AZ876 is a novel high-affinity LXR agonist.
  • HY-111498
    RGX-104 Agonist
    RGX-104 is a small-molecule LXR agonist that modulates innate immunity via transcriptional activation of the ApoE gene.
  • HY-N3216
    Nagilactone B Agonist >98.0%
    Nagilactone B, extracted from the root bark of Podocarpus nagi, is a liver X receptor (LXR) agonist.
  • HY-109073
    Rovazolac Modulator 99.82%
    Rovazolac is a liver x receptor (LXR) modulator extracted from patent WO2013130892A1.
  • HY-N0835
    (20S)-Protopanaxatriol Inhibitor >98.0%
    (20S)-Protopanaxatriol is a metabolite of ginsenoside, works through the glucocorticoid receptor (GR) and oestrogen receptor (ER), and is also a LXRα inhibitor and a PPARγ activator.
  • HY-108688
    GSK2033 Antagonist 98.83%
    GSK2033 is a LXR antagonist with pIC50s of 7 and 7.4 for LXRα or LXRβ, respectively.
  • HY-N2371
    27-Hydroxycholesterol Agonist 99.20%
    27-Hydroxycholesterol is a selective estrogen receptor modulator and an agonist of the liver X receptor.
  • HY-101442
    SR9238 Antagonist 99.53%
    SR9238 is a synthetic LXR antagonist with IC50s of 214 nM and 43 nM for LXRα and LXRβ, respectively.
  • HY-19919
    BMS-779788 Agonist >98.0%
    BMS-779788 is a LXR partial agonist with IC50 values of 68 nM for LXRα and 14 nM for LXRβ.
  • HY-N2370
    24-Hydroxycholesterol Activator >98.0%
    24-Hydroxycholesterol is a natural sterol, which serves as a positive allosteric modulator of N-Methyl-d-Aspartate (NMDA) receptorsR, and a potent activator of the transcription factors LXR.
  • HY-101973
    BMS-852927 Agonist 99.11%
    BMS-852927 is an LXRβ-selective agonist.
  • HY-10627
    GW3965 Agonist
    GW3965 is a potent, selective LXR agonist for hLXRα and hLXRβ with EC50 of 190 and 30 nM, respectively.